Author
Listed:
- Wenfang Chen
(Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center
University of Texas Southwestern Medical Center
the First Affiliated Hospital of Sun Yat-sen University)
- Haley Hill
(Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center
University of Texas Southwestern Medical Center)
- Alana Christie
(Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center)
- Min Soo Kim
(Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center
University of Texas Southwestern Medical Center)
- Eboni Holloman
(Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center
University of Texas Southwestern Medical Center)
- Andrea Pavia-Jimenez
(Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center
University of Texas Southwestern Medical Center)
- Farrah Homayoun
(Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center
University of Texas Southwestern Medical Center)
- Yuanqing Ma
(Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center
University of Texas Southwestern Medical Center)
- Nirav Patel
(Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center
University of Texas Southwestern Medical Center)
- Paul Yell
(Parkland Health and Hospital System)
- Guiyang Hao
(University of Texas Southwestern Medical Center)
- Qurratulain Yousuf
(Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center
University of Texas Southwestern Medical Center)
- Allison Joyce
(Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center
University of Texas Southwestern Medical Center)
- Ivan Pedrosa
(Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center
University of Texas Southwestern Medical Center)
- Heather Geiger
(New York Genome Center)
- He Zhang
(Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center
University of Texas Southwestern Medical Center)
- Jenny Chang
(Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center)
- Kevin H. Gardner
(Structural Biology Initiative, CUNY Advanced Science Research Center
City College of New York
Biochemistry, Chemistry and Biology Ph.D. Programs, Graduate Center, City University of New York)
- Richard K. Bruick
(Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center
University of Texas Southwestern Medical Center)
- Catherine Reeves
(New York Genome Center)
- Tae Hyun Hwang
(Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center
University of Texas Southwestern Medical Center)
- Kevin Courtney
(Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center
University of Texas Southwestern Medical Center)
- Eugene Frenkel
(Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center
University of Texas Southwestern Medical Center)
- Xiankai Sun
(Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center
University of Texas Southwestern Medical Center)
- Naseem Zojwalla
(Peloton Therapeutics Inc.)
- Tai Wong
(Peloton Therapeutics Inc.)
- James P. Rizzi
(Peloton Therapeutics Inc.)
- Eli M. Wallace
(Peloton Therapeutics Inc.)
- John A. Josey
(Peloton Therapeutics Inc.)
- Yang Xie
(Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center
University of Texas Southwestern Medical Center)
- Xian-Jin Xie
(Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center
University of Texas Southwestern Medical Center)
- Payal Kapur
(Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center
University of Texas Southwestern Medical Center)
- Renée M. McKay
(Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center
University of Texas Southwestern Medical Center)
- James Brugarolas
(Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center
University of Texas Southwestern Medical Center)
Abstract
The HIF-2 antagonist PT2399 is tested in mice bearing tumourgrafts derived from human renal cell cancers to demonstrate its efficacy, identify markers of sensitivity and characterize its effects.
Suggested Citation
Wenfang Chen & Haley Hill & Alana Christie & Min Soo Kim & Eboni Holloman & Andrea Pavia-Jimenez & Farrah Homayoun & Yuanqing Ma & Nirav Patel & Paul Yell & Guiyang Hao & Qurratulain Yousuf & Allison , 2016.
"Targeting renal cell carcinoma with a HIF-2 antagonist,"
Nature, Nature, vol. 539(7627), pages 112-117, November.
Handle:
RePEc:nat:nature:v:539:y:2016:i:7627:d:10.1038_nature19796
DOI: 10.1038/nature19796
Download full text from publisher
As the access to this document is restricted, you may want to
for a different version of it.
Citations
Citations are extracted by the
CitEc Project, subscribe to its
RSS feed for this item.
Cited by:
- Jin Zhou & Austin Hepperla & Jeremy M. Simon & Kangsan Kim & Qing Hu & Chuanhai Zhang & Lei Dong & Lianxin Hu & Cheng Zhang & Chengheng Liao & Alice Fang & Yayoi Adachi & Haoyong Fu & Tao Wang & Qian , 2025.
"SWI/SNF ATPase silenced HLF potentiates lung metastasis in solid cancers,"
Nature Communications, Nature, vol. 16(1), pages 1-19, December.
- Shuyan Dai & Lingzhi Qu & Jun Li & Ye Zhang & Longying Jiang & Hudie Wei & Ming Guo & Xiaojuan Chen & Yongheng Chen, 2022.
"Structural insight into the ligand binding mechanism of aryl hydrocarbon receptor,"
Nature Communications, Nature, vol. 13(1), pages 1-12, December.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:539:y:2016:i:7627:d:10.1038_nature19796. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.